Previous studies suggest that statins may have beneficial respiratory effects. However, it is unclear if these purported benefits vary with statin potency. Our objective was to determine if higher potency statins, compared with lower potency statins, were associated with a reduced risk of hospitalization for community-acquired pneumonia (HCAP).
Introduction
Treatment paradigms for the reduction of blood cholesterol have shifted recently, with new guidelines targeting 30-50% reductions in low-density lipoprotein (LDL) cholesterol for lower risk patients and 50% reductions for higher risk patients rather than targeting specific LDL cholesterol and non-high-density lipoprotein cholesterol levels [1, 2] . Consequently, new guidelines emphasize the potential cardiovascular benefits of a more aggressive lipid lowering approach using more potent statins. With this shift, there is a need for a more comprehensive assessment of the potential benefits and harms of higher potency statins relative to lower potency statins. Previous studies have found that higher potency statins are associated with increased risks of new-onset diabetes [3] and acute kidney injury [4] compared with lower potency statins. In contrast, with the anti-inflammatory and immune-modulatory properties of statins [5, 6] , higher potency statins may have beneficial effects on respiratory infections.
The JUPITER trial found that healthy patients without cardiovascular disease had a lower incidence of pneumonia with 20 mg rosuvastatin, a higher potency statin, than with placebo (risk ratio: 0.81, 95% confidence interval [CI]: 0.67-0.97) [7] . Observational studies also have examined the association between statins and pneumonia, producing conflicting results. These studies include two studies that reported significant reductions in pneumonia among statin users compared with nonusers: one was conducted in patients with diabetes (odds ratio [OR] : 0.49, 95% CI: 0.35-0.69) [8] , and the other was conducted in the general population (OR: 0.68, 95% CI: 0.63-0.73) [9] . In contrast, another study found no benefit of statin use compared with nonuse (OR: 1.61, 95% CI: 1.08-2.39), with the authors suggesting that the findings of previous studies comparing statin users to nonusers may be affected by "healthy user" bias [10] . With a reference group of nonuse, the results of such studies are difficult to interpret due to residual confounding.
Despite the ongoing debate regarding the potential benefits and harms of higher potency statins and the increasing use of higher potency statins in clinical practice, to our knowledge, no previous study has examined the association between statin potency and the risk of pneumonia. Our objective was to determine if higher potency statins, compared with lower potency statins, were associated with a reduced risk of hospitalization for community-acquired pneumonia (HCAP).
Methods

Data sources
We used data from the UK's Clinical Practice Research Datalink (CPRD), a clinical database that contains the medical records of 673 general practitioner practices [11] . It covers 11.3 million individuals and is a 6.9% representative sample of the entire UK population. The CPRD includes demographic information, lifestyle variables, diagnoses, clinical information, prescription information and laboratory data. CPRD data were linked to Hospital Episode Statistics data, which include primary and secondary in-hospital diagnoses as well as in-hospital procedure codes. The CPRD has been extensively validated [12] . This study was approved by the Independent Scientific Advisory Committee of the CPRD (protocol number 15_236, which was made available to journal reviewers) and the Research Ethics Board of the Jewish General Hospital in Montreal, Canada.
Study population
We identified all new users of statins (other than cerivastatin, which was withdrawn from the market in 2001) aged ≥40 years between April 1998 and October 2011. A new user was defined as a patient with no previous prescription for statins or other lipid lowering medications in the previous 365 days. The cohort entry date was defined by the date of the first statin prescription. We excluded patients who: (i) received prescriptions for multiple statins on the day of cohort entry to avoid exposure misclassification; (ii) were hospitalized with community-acquired pneumonia during the year before cohort entry to ensure that the patient did not develop pneumonia prior to the statin prescription; (iii) were hospitalized on the date of cohort entry and those hospitalized for any cause with a length of stay >1 day within 30 days before cohort entry to ensure that all observed cases of pneumonia were community-acquired and not hospital-acquired; (iv) had a diagnosis of cancer (other than nonmelanoma skin cancer) in the year before cohort entry due to the harmful effects of cancer and its treatments on the lungs; and (v) received a prescription for antituberculosis drugs in the year before cohort entry due to their association with respiratory disease. Patients were followed until an HCAP (defined below), death, departure from the CPRD or Hospital Episode Statistics, prescription of cerivastatin, multiple statin prescriptions on the same day, the end of the study period (31 st October 2011), the end of follow-up (730 days) or any hospitalization with a length of stay >1 day, whichever occurred first. Patients were censored upon hospitalization with a length of stay >1 day as any pneumonia that occurred soon after hospitalization would probably be nosocomial or hospital-acquired rather than community-acquired pneumonia, the outcome of interest. Since such patients were not considered at risk of the event of interest, their follow-up was censored at the time of hospitalization.
Case-control selection
Cases were defined as all patients with incident HCAP. To differentiate between community-acquired and nosocomial pneumonia, only those with an ICD-10 code (Table S1 ) [13] indicating the presence of pneumonia recorded on the day of admission or the day after admission were considered cases. Furthermore, only hospitalizations with a length of stay ≥1 day were considered as events, except for patients who died on their admission date. The index date for cases was defined by the day of follow-up on which hospital admission occurred. For each case, up to 10 controls were randomly selected using risk set sampling, with controls matched on sex, age (AE1 year), cohort entry date (AE90 days), and followup duration; for one case, the age caliper was widened to 2 years to identify an eligible control. The mean number of controls per case was 9.1 (standard deviation: 2.6), and the median was 10 (interquartile range, 10-10; Table S2 ).
In secondary analyses, we restricted our case series to fatal HCAPs, defined as cases of HCAP who died from any cause while in-hospital, those who died in-hospital from any cause within 30 days of admission, and all HCAPs with death within 30 days of admission, regardless of location.
Exposure definition
Statin prescriptions were classified according to their LDL-lowering ability [14] , with rosuvastatin ≥10 mg, atorvastatin ≥20 mg and simvastatin ≥40 mg classified as higher potency statins. Rosuvastatin <10 mg, atorvastatin <20 mg, simvastatin <40 mg, fluvastatin and pravastatin were classified as lower potency statins. This dichotomy is based on the ability to produce a 45% reduction in LDL cholesterol and has been used previously [3, 4] .
Cases and controls then were classified into four mutually-exclusive exposure categories: (i) current use of higher potency statin; (ii) current use of lower potency statin; (iii) recent use of any statin (regardless of potency); and (iv) past use of any statin. Current use was defined by a prescription whose duration +50% of that duration overlapped with the index date. Recent use was defined by a prescription whose duration +50% of that duration ended in the 1-90 days before the index date. Past use was defined by a prescription whose duration +50% of that duration ended >90 days before the index date. The exposure categories of recent and past use were included in our models to account for all person-time of observation during follow-up and to allow for the proper estimation of treatment effects of current use of higher potency statin compared with current use of lower potency statin. However, estimates for recent and past use are not presented as we were not interested in drawing inferences regarding these categories. In secondary analyses, duration of current exposure was subclassified as <120 days, 120-365 days, and 366-730 days.
Statistical analysis
Patient characteristics were summarized as counts with proportions for categorical data and means with standard deviations for continuous data, except in the case of skewed distributions, where medians and interquartile ranges were used. The overall rate of HCAP and corresponding 95% CI were estimated using Poisson regression. In our primary analysis, we used conditional logistic regression to estimate ORs and corresponding 95% CIs for HCAP with higher potency statins vs. lower potency statins; these ORs represent unbiased estimates of the hazard ratios (HRs) due to our use of risk set sampling [15] . To minimize confounding, we constructed high dimensional propensity scores [16] . We first created a propensity model with higher potency statin at cohort entry as the dependent variable; this model included obesity, alcohol abuse, use of more than four drug classes in the prior year, more than four general practitioner visits in the past year, diabetes, hypertension, prior myocardial infarction, prior stroke, prior coronary revascularization and 500 empirically identified covariates using the validated high dimensional propensity score macro (available at http://www.drugepi. org/dope-downloads/). From each prespecified data dimension, the algorithm assesses the prevalence of each covariate, the recurrence of each covariate, and finally prioritizes each covariate based on its bias-inflation factor to empirically identify confounders of the exposure-outcome association. Diagnoses and medications were measured in the year before cohort entry, and lifestyle variables were assessed in the 5 years before cohort entry using the value closest to the date of cohort entry. The c-statistic for our propensity score model was 0.78 ( Figure S1 ).
We adjusted our conditional logistic regression models (the outcome model) for smoking (ever, never, missing), history of asthma, chronic obstructive pulmonary disease (COPD) or nonhospitalized pneumonia in the year before cohort entry, use of immunosuppressive agents, inhaled bronchodilators, inhaled corticosteroids, systemic antibiotics, systemic corticosteroids, pneumococcal vaccine, influenza vaccine, and propensity score decile. We also included an indicator variable in our outcome model for an index date during summer (defined as April to September) due to the seasonal variations in respiratory outcomes such as HCAP.
In secondary analyses, we repeated our primary analyses with our case series restricted to fatal HCAP. In addition, we examined the impact of duration of current exposure on the rate of HCAP. We conducted three sensitivity analyses. First, we used grace periods of 25% and 75% of the prescription duration. Second, we repeated our case series restricted to those with a primary diagnosis of pneumonia. Third, we repeated our primary analysis using traditional adjustment to estimate the amount of residual confounding removed by our use of high dimensional propensity scores. Traditional adjustment involved the use of a conditional logistic regression model that included exposure and the predefined confounders as covariates but did not include the propensity score. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Results
Study population
The study cohort consisted of 348 428 patients (Figure 1 ), 217 721 of whom entered the cohort on a lower potency statin and 130 707 of whom entered the cohort on a higher potency statin. The study cohort resulted in 2251 incident cases of HCAP during a total of 561 886 person-years of observation (crude rate: 4.0 HCAP per 1000 persons per year, 95% CI: 3.8-4.2). A total of 547 (0.2%) patients were censored due to the prescription of cerivastatin, 770 (0.2%) patients were censored due to multiple statin prescriptions on the same day, and 57 952 patients (16.6%) were censored due to hospitalization with a length of stay >1 day.
There were several notable differences in the baseline characteristics of the 2251 cases of HCAP and their 22 178 matched controls (Table 1) . Cases were more likely to have a history of ever smoking and a higher prevalence of asthma, COPD, pneumonia, and cardiovascular-related comorbidities. In addition, cases had a higher prevalence of medication use, including use of respiratory drugs, immunosuppressive agents, systemic antibiotics and systemic corticosteroids. Importantly, cases and controls had a similar prevalence of use of pneumococcal vaccine.
There were also some differences between the 10 439 current users of lower potency statins and 7356 users of higher potency statin among controls (Table S3 ). Current users of a higher potency statin were more likely to have asthma, COPD, pneumonia and cardiovascular-related comorbidities. In contrast, lower potency statin users had a higher Figure 1 Flow diagram describing the construction of the study cohort prevalence of diabetes mellitus. There were no notable differences in sex, age, body mass index, smoking, and use of pneumococcal vaccine, immunosuppressive agents and system antibiotics.
Statin potency and HCAP
Compared with lower potency statins, higher potency statins were associated with an increased rate of HCAP (adjusted HR: 1.14; 95% CI: 1.03-1.27; Table 2 ). No clear duration-response relationship was present (Table 2) .
In secondary analyses, higher potency statins were associated with a higher risk of fatal HCAP compared with lower potency statins (adjusted HR: 1.29; 95% CI: 1.04-1.59; Table 3 ). Similar results were obtained when using alternate fatal HCAP definitions.
Sensitivity analyses
We conducted three sensitivity analyses. First, similar results were obtained when varying the grace period to 25% and 75% of prescription duration (Table S4) . Second, we repeated our primary analysis with our case series restricted to those with a primary diagnosis of pneumonia, which produced results that were consistent with those of our primary analysis, although not significant (Table S5 ). Third, we repeated our analysis using traditional adjustment, which also produced results that were consistent with those of our primary analysis (Table S6) .
Discussion
In this population-based cohort study, higher potency statins were not associated with a decreased risk of HCAP compared with lower potency statins. We also found no evidence of a duration-response relationship. While we hypothesized that higher potency statins would be associated with a decreased risk of HCAP based on the findings of the placebo-controlled JUPITER trial [7] , increased risks of HCAP and of fatal HCAP with higher potency statins were observed. The observed risk warrants careful consideration and further study given the recent shift towards a more aggressive approach to lipid lowering, particularly given the previously reported risks of other adverse effects with higher potency statins [3, 4] compared to lower potency statins. Observational studies have previously examined the effect of statin use on the risk of pneumonia and related outcomes; however, all of these previous studies compared the risk among statin users to that of nonusers [8, 9, 17, 18] , and the comparability of these patients is unclear. These concerns are supported by a study by Dormuth et al. [19] , who documented that patients who are adherent to statin therapy are more likely to have health-seeking behaviours than those who are not. A subsequent systematic review concluded that no convincing evidence was available regarding the statinpneumonia relationship due to the presence of substantial clinical and statistical heterogeneity [20] . Moreover, to our knowledge, the association between statin potency and HCAP has not been examined previously. One previous study examined the pneumonia risk of individual statins, reporting a lower risk of pneumonia with pravastatin (a lower potency statin; OR: 0.73; 95% CI: 0.52-1.02) than with simvastatin (OR: 1.00; 95% CI: 0.86-1.15) or atorvastatin (OR: 0.95; 95% CI: 0.79-1.13) [9] . However, the exposure definition used in this study did not consider the prescribed daily dose, preventing the examination of statin potency per se.
The effects of statins on other respiratory outcomes have also been examined. These include two randomized controlled trials examining the effect of two individual statins compared with placebo on ventilator-associated pneumonia (VAP). The first, conducted using 60 mg simvastatin (a higher potency statin), found a nonsignificant protective effect [21] , whereas the second, conducted using 40 mg pravastatin (a lower potency statin), led to a decrease in VAP and increased survival [22] . Although these two randomized controlled trials targeted VAP, the results were consistent with those of the present study, suggesting that higher potency statins may not have respiratory benefits relative to lower potency statins. Available evidence also suggests that statins may have a beneficial role in the treatment of COPD [23] , including beneficial effects of pravastatin (a lower potency statin) on exercise tolerance in these patients [24] . In contrast, a recent trial found that 40 mg simvastatin (a higher potency statin) had no effect on exacerbation rates in patients with COPD [25] , which is consistent with our results.
The biological mechanism responsible for a possible association between statins and HCAP remains unclear, although several hypotheses have been suggested. Some studies have suggested that the pleiotropic effects of statins, including anti-inflammatory effects [6, 26] , increased immune response [6, 26] and improved endothelial cell function [24] , may play a role. While we did not find protective effects with higher potency statins, it is possible that the pleiotropic effects of statins do not differ with statin potency and that the use of an active comparator (i.e., lower potency statins) may therefore have masked these effects. To our knowledge, there is no basic science evidence that supports our observed increase in HCAP with higher potency statins relative to lower potency statins. The observed increase in our study may also be the result of residual confounding, underscoring the need for further research of the purported mechanism of the respiratory effects of statins.
Our study has several strengths. First, this study is less susceptible to healthy-user bias by using active comparator. This is particularly important in the study of the unintended benefits of statins as previous studies have documented that patients who adhere to statins are more likely to seek out preventive services and less likely to have accidents [19, 27, 28] . Second, protection against confounding was also provided by our use of high-dimensional propensity scores, rigorous matching, and statistical adjustment. Third, we had the statistical power to assess this issue robustly. Fourth, while respiratory illnesses, such as pneumonia, COPD and acute asthma exacerbations, may be misdiagnosed as one or the other, we applied a validated algorithm for HCAP [13] , minimising potential misclassification.
Our study also has some limitations. First, despite our use of an active comparator, matching and rigorous adjustment, residual confounding is possible. Second, our outcome definition was restricted to hospitalized cases of communityacquired pneumonia. Consequently, patients with mild cases of community-acquired pneumonia that did not require hospitalization were not included in our case series. We focused on hospitalized cases because we believe they are the most clinically relevant. Finally, the CPRD contains prescriptions issued rather than drug dispensations. Consequently, some exposure misclassification is possible.
Conclusions
Compared with lower potency statins, higher potency statins were not associated with a decreased risk of HCAP. Contrary to our hypothesis, we observed increased risks of HCAP and of fatal HCAP with higher potency statins. Given these unexpected findings and the recent shift to a more aggressive approach to lipid lowering, the observed increased risk warrants further investigation. 
Supporting Information
Additional Supporting Information may be found in the online version of this article at the publisher's web-site:
http://onlinelibrary.wiley.com/doi/10.1111/bcp.13208/suppinfo Table S4 Sensitivity analyses examining the association between the use of higher potency statin and HCAP compared with lower potency statin, using grace periods of 25% and 75% of the prescription duration Table S5 Sensitivity analyses examining the association between the use of higher potency statin and HCAP compared with lower potency statin restricted to cases with a primary diagnosis of pneumonia Table S6 Sensitivity analyses examining the association between the use of higher potency statin and HCAP compared with lower potency statin, using traditional covariate adjustment Figure S1 Densities of propensity score between higher potency and lower potency statin users
